ILC3 Functional Regulation Mechanisms

Scope

This topic page organizes mechanisms that regulate ILC3 function in the current ILC_in_lung wiki. It focuses on cytokine activation, stromal niche control, transcriptional identity, circadian and metabolic regulation, vitamin D/IL-23 signaling, AHR, STING, ER stress, glucocorticoid resistance, and tissue-context boundaries.

For disease outcomes, see ILC3 Roles In Pulmonary Disease.

Evidence tags

#cell/ILC3 #tissue/lung #tissue/gut #assay/flow #assay/RNAseq #assay/scRNAseq #assay/in_vivo #assay/in_vitro #outcome/infection #outcome/inflammation #outcome/airway_hyperresponsiveness #axis/ILC_lung_homeostasis #axis/ILC_airway_inflammation #axis/ILC_plasticity

Confidence snapshot

• High confidence: IL-1beta, IL-23, RORgammat-associated identity, IL-22, and IL-17A are central organizing concepts for ILC3 regulation in the source set.
• High confidence: pulmonary ILC3 function can be shaped by stromal niches, including IGF1 in newborn lung and SCF/KIT signaling in neutrophilic asthma.
• Medium confidence: circadian control, vitamin D, AHR, STING, nutrition/iron, and ER-stress pathways are important cross-tissue ILC3 regulatory mechanisms.
• Medium confidence: gut/mucosal ILC3 regulation also includes RANKL/RANK restraint, FFAR2 metabolite sensing, VIP neuroimmune circuits, trained ILC3 defense states, and HB-EGF tissue-protection output; these are mechanism context unless matched lung evidence is present.

• Medium-high confidence: BACH2-PPARgamma and LINGO4-linked pathways support metabolic/homeostatic control of gut ILC3s, while dysbiosis and fungal-infection sources support lung-relevant type 3 inflammatory and plasticity branches (BACH2 controls ILC3 function via PPARgamma-dependent mitochondrial metabolism; LINGO4 coordinates ILC3-intrinsic IL-22 production and microbiota-mediated ILC3 homeostasis; Microbial dysbiosis sculpts a systemic ILC3/IL-17 axis governing lung inflammatory responses and central hematopoiesis; Innate lymphoid cells integrate sensing and plasticity to control fungal infections).

• Medium confidence: glucocorticoid resistance in ILC3s is a disease-relevant regulatory mechanism for non-eosinophilic or steroid-resistant asthma.

• Low confidence: many detailed ILC3 regulatory mechanisms come from gut or mucosal sources and require explicit tissue labels before being applied to lung.

Established observations

Cytokine activation and effector output

• ILC3s are generally organized around RORgammat-associated identity and production of IL-22 and/or IL-17-family cytokines.
• Activation of Type 3 innate lymphoid cells and interleukin 22 secretion in the lungs during Streptococcus pneumoniae infection supports IL-23-responsive lung ILC3 IL-22 production during bacterial infection.
• Pulmonary fibroblast-derived stem cell factor promotes neutrophilic asthma by augmenting IL-17A production from ILC3s frames ILC3s as IL-1beta/IL-23-responsive cells capable of IL-17 and IL-22 production, with IL-17A linked to neutrophilic asthma outcomes.
• Group 3 innate lymphoid cells secret neutrophil chemoattractants and are insensitive to glucocorticoid via aberrant GR phosphorylation supports IL-1beta-induced CXCL8/CXCL1 production from ILC3s through NF-kappaB and MAPK-linked pathways.
• Interleukin-17-producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity adds an upstream macrophage-NLRP3-IL-1beta licensing branch for CCR6-positive IL-17-producing innate lymphoid cells in obesity-associated airway disease.

Stromal and developmental niche regulation

• Insulin-like Growth Factor 1 Supports a Pulmonary Niche that Promotes Type 3 Innate Lymphoid Cell Development in Newborn Lungs supports a pulmonary stromal niche mechanism in which alveolar fibroblast-derived IGF1 promotes postnatal lung ILC3 development.
• Pulmonary fibroblast-derived stem cell factor promotes neutrophilic asthma by augmenting IL-17A production from ILC3s supports a disease-associated stromal mechanism in which pulmonary fibroblast-derived SCF augments ILC3 IL-17A production.

• Together, these sources suggest that stromal cells can support either development/homeostasis or inflammatory output depending on context.

• Divergent ILC3 responses to PDGF-D control mucosal immunity reinforces species-aware ILC3 interpretation: PDGF-D can promote mouse IL-22/proliferation through PDGFRbeta but type 1-like TNF-alpha/IFN-gamma output through NKp44 engagement in humanized receptor context.

Transcriptional identity and plasticity

• Reciprocal transcription factor networks govern tissue-resident ILC3 subset function and identity supports transcription-factor-network control of ILC3 subset function and identity.
• Circadian circuits control plasticity of group 3 innate lymphoid cells by sustaining epigenetic configuration of RORgammat supports circadian control of ILC3 identity through maintenance of RORgammat-associated epigenetic configuration, though this is primarily gut-context evidence.
• WASH maintains NKp46+ ILC3 cells by promoting AHR expression supports AHR-linked maintenance of an NKp46+ ILC3 branch.

Taxonomy and IL-17 classification boundaries

• Differentiation of type 1 ILCs from a common progenitor to all helper-like innate lymphoid cell lineages supports conservative separation of helper-like ILC lineages from conventional NK cells when interpreting ILC1-like, ILC2, and ILC3 states.
• Tissue residency of innate lymphoid cells in lymphoid and nonlymphoid organs supports tissue residency as an organizing concept for ILC interpretation rather than assuming all ILC-like signals reflect circulating contamination.

• c-Kit-positive ILC2s exhibit an ILC3-like signature that may contribute to IL-17-mediated pathologies is a classification warning: IL-17-producing ILC-like states can include ILC2/ILC3-like boundary populations and should not automatically be called bona fide ILC3s without marker and context support.

• Interleukin-17D regulates group 3 innate lymphoid cell function through its receptor CD93 supports a gut epithelial IL-17D/CD93 branch that promotes ILC3 IL-22 and antimicrobial peptide programs.

• Nucleophosmin 1 promotes mucosal immunity by supporting mitochondrial oxidative phosphorylation and ILC3 activity supports a gut-labeled NPM1-p65-TFAM mitochondrial OXPHOS branch for ILC3 IL-22 activity.

Vitamin D, AHR, STING, nutrition, and ER stress

• Vitamin D downregulates the IL-23 receptor pathway in human mucosal group 3 innate lymphoid cells supports vitamin D-mediated suppression of IL-23 pathway responses and ILC3 cytokine production in human mucosal ILC3s.
• AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch and WASH maintains NKp46+ ILC3 cells by promoting AHR expression support AHR as a recurring ILC3/ILC22 regulatory axis.
• ILC3s sense gut microbiota through STING to initiate immune tolerance supports STING as a gut ILC3 microbiota-sensing/tolerance mechanism.
• Nutrition impact on ILC3 maintenance and function centers on a cell-intrinsic CD71-iron axis supports a nutrition/iron-linked ILC3 maintenance branch.
• The IRE1alphaXBP1 pathway sustains cytokine responses of group 3 innate lymphoid cells in inflammatory bowel disease supports an ER-stress/UPR-linked mechanism for ILC3 cytokine responses in IBD.
• BACH2 controls ILC3 function via PPARgamma-dependent mitochondrial metabolism supports a gut ILC3 BACH2-PPARgamma-OXPHOS branch that sustains ILC3 function and colitis restraint in the reported systems.
• LINGO4 coordinates ILC3-intrinsic IL-22 production and microbiota-mediated ILC3 homeostasis supports a gut ILC3 LINGO4-STAT3/mitochondrial-fitness branch that coordinates IL-22 production and microbiota-dependent ILC3 homeostasis.

Gut/mucosal timing, metabolite, neuroimmune, and repair circuits

• The Tumor Necrosis Factor Superfamily Member RANKL Suppresses Effector Cytokine Production in Group 3 Innate Lymphoid Cells supports a gut CCR6-positive ILC3 RANKL/RANK restraint branch that limits IL-17A and IL-22 output.
• A circadian clock is essential for homeostasis of group 3 innate lymphoid cells in the gut and Light-entrained and brain-tuned circadian circuits regulate ILC3s and gut homeostasis support circadian and organism-level timing control of intestinal ILC3 homeostasis.
• Metabolite-Sensing Receptor Ffar2 Regulates Colonic Group 3 Innate Lymphoid Cells and Gut Immunity supports microbial-metabolite sensing through FFAR2 as a colonic ILC3 expansion and IL-22-output mechanism.
• Feeding-dependent VIP neuron-ILC3 circuit regulates the intestinal barrier, The neuropeptide VIP confers anticipatory mucosal immunity by regulating ILC3 activity, and Vasoactive intestinal peptide promotes host defense against enteric pathogens by modulating the recruitment of group 3 innate lymphoid cells show that VIP-linked neuroimmune control can either restrain IL-22 through VIPR2 or support ILC3 recruitment/defense through VPAC1 depending on receptor and context.
• Trained ILC3 responses promote intestinal defense supports durable trained ILC3 defense after enteric challenge, while Group 3 innate lymphoid cells produce the growth factor HB-EGF to protect the intestine from TNF-mediated inflammation adds an ILC3 growth-factor tissue-protection branch.
• Activation and Suppression of Group 3 Innate Lymphoid Cells in the Gut is useful as review-level orientation for gut ILC3 regulatory inputs and brakes.
• ZBTB46 defines and regulates ILC3s that protect the intestine, Context-dependent role of group 3 innate lymphoid cells in mucosal protection, Circadian circuits control plasticity of group 3 innate lymphoid cells by sustaining epigenetic configuration of RORgammat, Enteric GABAergic neuron-derived gamma-aminobutyric acid initiates expression of Igfbp7 to sustain ILC3 homeostasis, and ILC3s promote intestinal tuft cell hyperplasia and anthelmintic immunity through RANK signaling extend the gut ILC3 context around identity, timing, neuroimmune homeostasis, and epithelial crosstalk.

Glucocorticoid resistance and inflammatory signaling

• Group 3 innate lymphoid cells secret neutrophil chemoattractants and are insensitive to glucocorticoid via aberrant GR phosphorylation supports a mechanism where ILC3 neutrophil chemoattractant production is glucocorticoid-insensitive and linked to altered glucocorticoid receptor phosphorylation.
• This source is especially important for steroid-resistant or non-eosinophilic asthma because it links cell function, inflammatory mediator production, and drug-response biology.

Adaptive-immunity regulation

• Innate lymphoid cells regulate CD4+ T-cell responses to intestinal commensal bacteria and Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4+ T cells support a gut ILC3-MHCII branch that restrains commensal-specific CD4 T-cell responses.
• Innate lymphoid cells support regulatory T cells in the intestine through interleukin-2 and ILC3s select microbiota-specific regulatory T cells to establish tolerance in the gut support intestinal ILC3-Treg maintenance and selection branches.
• Human CD40 ligand-expressing type 3 innate lymphoid cells induce IL-10-producing immature transitional regulatory B cells supports a human tonsil/blood ILC3-CD40L/BAFF/IL-15 regulatory B-cell branch.
• These mechanisms are central to ILC3 adaptive-immunity regulation but should stay gut/tonsil/blood-labeled unless direct lung evidence is added; see ILC Regulation Of Adaptive Immunity.
• Additional source-reviewed context now separates indirect ILC3-myeloid-Treg support, STING-linked microbiota sensing, CNS inflammatory antigen presentation, colon-cancer immunotherapy biology, and RORgammat-positive DC lineage boundaries (Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis; ILC3s sense gut microbiota through STING to initiate immune tolerance; Antigen-presenting innate lymphoid cells orchestrate neuroinflammation; Dysregulation of ILC3s unleashes progression and immunotherapy resistance in colon cancer; RORgammat+ dendritic cells are a distinct lymphoid-derived lineage).

Checkpoint restraint and IL-23 counter-regulation

• CTLA-4-expressing ILC3s restrain interleukin-23-mediated inflammation supports an extrapulmonary checkpoint branch in which IL-23 can induce CTLA-4-positive ILC3s that restrain inflammatory T-cell programs; in this wiki it should be used as gut-labeled mechanism context rather than direct pulmonary proof.

Pulmonary infection and severe-asthma boundary branches

• Mtb infection adds a protective IL-17/IL-22-CXCL13 regulatory branch for ILC3s in early pulmonary granuloma organization, distinct from IL-17-associated asthma or ARDS pathology (Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis).
• Human severe-asthma sputum reinforces the classification problem for IL-17+ ILCs: bona fide ILC3s, c-kit+ IL-17A+ intermediate ILC2s, and mixed inflammatory airway states require separate marker and compartment labels (A population of c-kit+ IL-17A+ ILC2s in sputum from individuals with severe asthma supports ILC2 to ILC3 trans-differentiation).
• Innate lymphoid cells integrate sensing and plasticity to control fungal infections adds direct mouse lung fungal-infection evidence in which fungal sensing and inflammatory cytokines promote ILC activation and ILC3-like skewing; lineage and transfer context should remain explicit.
• Microbial dysbiosis sculpts a systemic ILC3/IL-17 axis governing lung inflammatory responses and central hematopoiesis adds a mouse gut-lung type 3 inflammation branch in which streptomycin dysbiosis primes IL-23-linked lung ILC3/Th17 responses during hypersensitivity pneumonitis.

Interpretation

ILC3 regulation should be interpreted as a balance between identity-maintaining programs and inflammatory activation programs. RORgammat, AHR, circadian regulation, nutrition/iron, and stromal survival cues support identity and maintenance. IL-1beta, IL-23, SCF/KIT, NF-kappaB/MAPK, and disease-associated stromal signals can push ILC3s toward IL-17A, neutrophil chemoattractants, and inflammatory pathology. Vitamin D and CTLA-4-like restraint mechanisms may counter inflammatory IL-23-linked activity in some mucosal contexts. The map below separates maintenance-supporting, inflammatory, and restraining branches so positive and negative regulation are both explicit.

Identity and maintenance

flowchart TB
    accTitle: ILC3 Identity And Maintenance
    accDescr: Compact vertical map of ILC3 identity and maintenance programs.

    support["Support cues"]
    rorgt["RORgammat"]
    ahr["AHR / WASH"]
    clock["Circadian"]
    iron["CD71 / iron"]
    igf1["IGF1 niche"]
    sting["STING"]
    ilc3["ILC3"]
    il22["IL-22"]
    tissue["barrier / niche"]

    support --> rorgt
    support --> ahr
    support --> clock
    support --> iron
    support --> igf1
    support --> sting
    rorgt --> ilc3
    ahr --> ilc3
    clock --> ilc3
    iron --> ilc3
    igf1 --> ilc3
    sting --> ilc3
    ilc3 --> il22
    il22 --> tissue

    classDef support_class fill:#e8f3ff,stroke:#3b6ea8,stroke-width:2px,color:#17324d
    classDef cell fill:#f6eefc,stroke:#7a55a3,stroke-width:2px,color:#2d1645
    classDef out fill:#eef7ed,stroke:#4d8a50,stroke-width:2px,color:#173d1d
    class support,rorgt,ahr,clock,iron,igf1,sting support_class
    class ilc3 cell
    class il22,tissue out

Inflammatory activation

flowchart TB
    accTitle: ILC3 Inflammatory Activation
    accDescr: Compact vertical map of inflammatory ILC3 regulatory inputs and outputs.

    trigger["Inflammatory cues"]
    il1il23["IL-1b / IL-23"]
    scf["SCF / KIT"]
    nfkb["NF-kB / MAPK"]
    xbp1["XBP1"]
    gr["GR resistance"]
    ilc3["ILC3"]
    il17["IL-17A"]
    chemokine["CXCL1 / CXCL8"]
    neutrophil["neutrophilic disease"]

    trigger --> il1il23
    trigger --> scf
    trigger --> nfkb
    trigger --> xbp1
    trigger --> gr
    il1il23 --> ilc3
    scf --> ilc3
    nfkb --> ilc3
    xbp1 --> ilc3
    gr --> ilc3
    ilc3 --> il17
    ilc3 --> chemokine
    il17 --> neutrophil
    chemokine --> neutrophil

    classDef cue fill:#fff4de,stroke:#b47a1f,stroke-width:2px,color:#4a3108
    classDef cell fill:#f6eefc,stroke:#7a55a3,stroke-width:2px,color:#2d1645
    classDef out fill:#eef7ed,stroke:#4d8a50,stroke-width:2px,color:#173d1d
    class trigger,il1il23,nlrp3,scf,nfkb,xbp1,gr cue
    class ilc3 cell
    class il17,chemokine,neutrophil out

Restraint and classification

flowchart TB
    accTitle: ILC3 Restraint And Classification
    accDescr: Compact vertical map of ILC3 restraint pathways and IL-17 classification boundaries.

    ilc3["ILC3"]
    brake["Restraint"]
    vitd["Vitamin D"]
    ctla4["CTLA-4"]
    lower["lower output"]
    boundary["IL-17+ ILC"]
    bona["bona fide ILC3"]
    ilc2like["c-kit+ ILC2"]
    mixed["mixed gate"]

    vitd --> brake
    ctla4 --> brake
    brake -.-> ilc3
    ilc3 -.-> lower
    boundary --> bona
    boundary --> ilc2like
    boundary --> mixed

    classDef brake_class fill:#f4f4f4,stroke:#777,stroke-width:1px,color:#222
    classDef cell fill:#f6eefc,stroke:#7a55a3,stroke-width:2px,color:#2d1645
    classDef warn fill:#fff4de,stroke:#b47a1f,stroke-width:2px,color:#4a3108
    class brake,vitd,ctla4,lower brake_class
    class ilc3 cell
    class boundary,bona,ilc2like,mixed warn

Contradiction and supersession

• Contradiction: IL-23/IL-1beta pathways can support protective mucosal responses but can also drive neutrophilic inflammation and steroid-resistant asthma.
• Contradiction: AHR and circadian/RORgammat mechanisms are strong ILC3 identity regulators, but much of this evidence is gut or mucosal rather than lung-specific.
• Contradiction: stromal signals can support newborn lung ILC3 development or augment pathogenic IL-17A production depending on the stromal signal and disease context.
• Supersession: no current source supersedes the full ILC3 regulatory map. The correct approach is to annotate mechanism by tissue, species, and outcome.

Open questions

• Which ILC3 regulatory mechanism is most relevant to the user's lung dataset: IL-23/IL-1beta, SCF/KIT, IGF1, AHR, RORgammat, vitamin D, STING, or glucocorticoid resistance?
• Are ILC3 outputs measured as cytokine transcripts, intracellular cytokine staining, secreted protein, or downstream neutrophil recruitment?
• Are apparent ILC3s distinguished from Th17, gamma-delta T, NK, ILC1, and ILC2/ILC3-like plastic states?
• Does the project have stromal, epithelial, or macrophage ligand data that could explain ILC3 activation?
• Is the disease model eosinophilic, neutrophilic, mixed, infection-driven, or injury-driven?

Related pages

• ILC3
• ILC3 Roles In Pulmonary Disease
• Lung ILC Disease Roles Companion
• ILC In Lung

Future Expansion Directions

This short appendix highlights future literature directions rather than current mechanistic conclusions. The most useful additions for later versions of this page would be:

• Additional ILC3 mechanism papers labeled as lung-specific, gut-specific, mucosal-general, or review-level evidence.
• A tighter regulatory table mapping mechanism to output: IL-22, IL-17A, CXCL1/CXCL8, GM-CSF, IFNG, or tissue-maintenance programs.
• More direct source coverage connecting the mechanism map back to the existing ILC3 hub, especially where extrapulmonary mechanism context is being used to frame pulmonary interpretation.